Kenneth Kolinsky

3.0k citations

33 papers · 2.3k indexed · 1 hit paper · h-index 19

Impact in

Oncology top 2%
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Cancer Research top 10%

Papers in

Oncology 24
- Cancer-related Molecular Pathways 8
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 7
- Colorectal Cancer Treatments and Studies 6
Molecular Biology 21
- Melanoma and MAPK Pathways 7
- Angiogenesis and VEGF in Cancer 6
- Ubiquitin and proteasome pathways 5

Co-authors: Kathryn Packman Brian Higgins David Heimbrook Christian Tovar Zoran Filipovic Binh Thanh Vu Holly Hilton James Rosinski
Journals: Molecular Cancer Therapeutics (5 papers)Cancer Research (5 papers)Journal of Clinical Oncology (4 papers)Cancer Chemotherapy and Pharmacology (2 papers)Clinical Cancer Research (1 paper)
Partner nations: United States Switzerland New Zealand

In The Last Decade

Kenneth Kolinsky

33 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy 2006 · 553 citations

Peers

Countries citing papers authored by Kenneth Kolinsky

Since Specialization

Citations

This map shows the geographic impact of Kenneth Kolinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Kolinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Kolinsky more than expected).

Fields of papers citing papers by Kenneth Kolinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Kolinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Kolinsky. The network helps show where Kenneth Kolinsky may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kenneth Kolinsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kenneth Kolinsky Line = papers co-authored together Kenneth Kolinsky links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach Clinical Cancer Research ·Brian Higgins, Kelli Glenn, Antje‐Christine Walz, Christian Tovar, Zoran Filipovic, K. Vogel, Jesse Drapekin, Kenneth Kolinsky, 啓輔上原, Behrooz Shafiei, Rosario Garrido, Michael Linn, Christophe Meille, David Heimbrook, Lyubomir T. Vassilev, Kathryn Packman	2014	50
2	MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models Cancer Research ·Christian Tovar, Bradford Graves, Kathryn Packman, Zoran Filipovic, J Guiserix, S WAGNER, Rosario Garrido, Jesse Drapekin, Kenneth Kolinsky, Kwong-Him To, Buse Tatar, Frank Podlaski, Peter M. Wovkulich, Binh Thanh Vu, Lyubomir T. Vassilev	2013	220
3	Efficacy of vemurafenib (V), a selective ^V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model. Journal of Clinical Oncology ·Brian P. Higgins, Kenneth Kolinsky, Kathleen Schostack, Gideon Bollag, Richard J. Lee, Fei Su, Kathryn Packman	2012	5
4	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su	2011	170
5	High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097 Molecular Oncology ·Wei He, Leopoldo Luistro, Daisy Carvajal, Melissa Smith, 王澤惠, Xuefeng Yin, James J. Cai, Brian Higgins, Kenneth Kolinsky, Elber Gomes Souza, Kathryn Packman, David Heimbrook, John F. Boylan	2011	38
6	Preclinical evaluation of the novel multi-targeted agent R1530 Cancer Chemotherapy and Pharmacology ·Kenneth Kolinsky, Christian Tovar, Yue Zhang, Aruna Railkar, Hong Yang, Daisy Carvajal, Thomas D. Nevins, Wanping Geng, Michael Linn, Kathryn Packman, Jinjun Liu, Zhuming Zhang, Peter M. Wovkulich, G Ju, Brian Higgins	2011	10
7	MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer Molecular Cancer ·Christian Tovar, Brian Higgins, Kenneth Kolinsky, Mingxuan Xia, Kathryn Packman, David Heimbrook, Lyubomir T. Vassilev	2011	36
8	Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models Molecular Cancer Therapeutics ·Sherif Daouti, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Huisheng Wang, Elber Gomes Souza, John Moliterni, Nicholas Huby, Nader Fotouhi, Taija Häätylä, Petra Goelzer, Harpreet Sandhu, Jiakui Li, Aruna Railkar, David Heimbrook, Huifeng Niu	2010	23
9	RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley P. Kolis, Sylvia Zhao, W. Jaskółowski, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su	2010	307
10	Pyrazolobenzodiazepines: Part I. Synthesis and SAR of a potent class of kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Jinjun Liu, ANGEL D BELLUSCI, Qingjie Ding, Brian Higgins, G Ju, Kenneth Kolinsky, 啓三黒瀬, Christine Lukacs, Giacomo Pizzolato, 信一郎原, Amy L. Swain, Kshitij Thakkar, R. F. Maronde, Jonathan Medina, Wang Chen-hua, Xuefeng Yin, Peter M. Wovkulich	2010	11
11	Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy Cell Cycle ·Christian Tovar, Brian Higgins, Dayanand Deo, Kenneth Kolinsky, Jinjun Liu, David Heimbrook, Lyubomir T. Vassilev	2010	24
12	Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy Cancer Research ·Sherif Daouti, Huisheng Wang, Wenhui Li, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Rafael Soares de Souza Pitombeira, Norman Kong, Nicholas Huby, Wen Yang, Qing Xiang, Frank Podlaski, Yang He, Nader Fotouhi, David Heimbrook, Huifeng Niu	2009	25
13	Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts. PubMed ·Kenneth Kolinsky, Yue Zhang, Ute Dugan, David Heimbrook, Kathryn Packman, Brian Higgins	2009	16
14	Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents Molecular Cancer Therapeutics ·Fei Su, Hong Yang, J. C. Conner, Jianping Chen, Kenneth Kolinsky, Kathryn Packman, David Heimbrook	2007	3
15	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy Proceedings of the National Academy of Sciences ·Christian Tovar, James Rosinski, Zoran Filipovic, Brian Higgins, Kenneth Kolinsky, Holly Hilton, Xiaolan Zhao, Binh Thanh Vu, Weiguo Qing, Kathryn Packman, Ola Myklebost, David Heimbrook, Lyubomir T. Vassilev Hit paper breakdown →	2006	553
16	Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models Cancer Chemotherapy and Pharmacology ·Jianping Chen, Melissa Smith, Kenneth Kolinsky, Behrooz Shafiei, Oluwadabira Adedoyin, Luke Fritzky, Mohammad Rashed, Eric B. Wheeldon, Michael Linn, Brian Higgins	2006	21
17	RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation Bioorganic & Medicinal Chemistry ·Lee McDermott, Mary Ellen Simcox, Brian Higgins, 王澤惠, Kenneth Kolinsky, Melissa Smith, Zhuoyu Mo, Imelda F.I M Pekei, Yingsi Chen, O Coltro, S. T. Dinnocenti, 古元淑子, De-Hui Zeng, Aruna Railkar, Louise Gerber, Kin‐Chun Luk	2005	17
18	Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models Anti-Cancer Drugs ·Brian Higgins, Kenneth Kolinsky, Melissa Smith, Gordon Beck, Mohammad Rashed, Behrooz Shafiei, Michael Linn, Eric B. Wheeldon, Franz Fotr, Herbert Birnboeck, Gerhard Hoffmann	2004	126
19	Interleukin‐12 Antagonist Activity of Mouse Interleukin‐12 p40 Homodimer in Vitro and in Vivo Annals of the New York Academy of Sciences ·Maurice K. Gately, Daisy Carvajal, Suzanne E. Connaughton, Silke Gillessen, Rajeev R. Warrier, Kenneth Kolinsky, Victoria L. Wilkinson, Francis Terry, Michaela Hoerner, Frank Podlaski, D A Faherty, Philip C. Familletti, A S Stern, David H. Presky	1996	118
20	Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. The Journal of Experimental Medicine ·Kim W. McIntyre, George Stepan, Kenneth Kolinsky, W R Benjamin, Julia M Cropper, K L Kaffka, Carolyn A. Campen, R Chizzonite, P L Kilian	1991	254

About Kenneth Kolinsky

Kenneth Kolinsky is a scholar working on Oncology, Molecular Biology, Cancer Research, Hepatology and Modeling and Simulation, having authored 33 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (8 papers), Cancer Treatment and Pharmacology (7 papers), Melanoma and MAPK Pathways (7 papers), HER2/EGFR in Cancer Research (7 papers), Colorectal Cancer Treatments and Studies (6 papers), Angiogenesis and VEGF in Cancer (6 papers), Ubiquitin and proteasome pathways (5 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Oncology (1.3k citations), Cancer Research (294 citations), Molecular Biology (1.3k citations), Immunology (326 citations) and Biotechnology (123 citations). Kenneth Kolinsky has collaborated with scholars based in United States, Switzerland and New Zealand. Frequent co-authors include Kathryn Packman, Brian Higgins, David Heimbrook, Christian Tovar, Zoran Filipovic, Binh Thanh Vu, Holly Hilton, James Rosinski, Lyubomir T. Vassilev and Ola Myklebost. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact